Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy
-- Taiwan Food and Drug Administration grants Accelerated Approval Designation (AAD) to Nefecon --
--Ministry of Food and Drug Safety in South Korea grants ODD to Nefecon --
-- Nefecon is a first-in-disease treatment for IgAN patients and has been approved in U.S. and E.U. --
SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today the Taiwan Food and Drug Administration and Ministry of Food and Drug Safety in South Korea have granted fast-tracked approval process to Nefecon®. Nefecon is our lead product in the renal disease portfolio as a first-in-disease treatment for primary immunoglobulin A nephropathy (IgAN) and a New Drug Application (NDA) has been accepted in mainland China.
"We are very pleased to receive accelerated review and approval process for Nefecon in Taiwan and South Korea, which will help bring this therapeutic option to patients in Asia faster," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "While primary IgAN has much higher prevalence in Asia than elsewhere in the world, there are no established treatments for patients living with the chronic condition, underscoring the significant and urgent unmet need for this innovative medicine."
The Taiwan Food and Drug Administration has granted Accelerated Approval Designation (AAD) to Nefecon, which will enable NDA submission and priority review of Nefecon based on topline results from Part A of NefIgArd, the pivotal global Phase 3 clinical trial. Meanwhile, the Ministry of Food and Drug Safety in South Korea granted ODDi for Nefecon, which will significantly accelerate NDA filing and approval with an increased probability of priority review designation. Earlier this month, the China National Medical Products Administration (NMPA) accepted Everest Medicines' NDA for Nefecon in mainland China, bringing Nefecon an important step closer to becoming the first-ever therapeutic option indicated for around 5 million IgAN patients in the country. The NMPA recommended Breakthrough Therapy Designation (BTD) for Nefecon for the treatment of IgAN in December 2020.
Everest Medicines announced in April 2022 that reduction in proteinuria and stabilization of eGFR in a Chinese subpopulation after 9 months of treatment with Nefecon were consistent with topline results from Part A of the pivotal global Phase 3 clinical trial NefIgArd, which were reported by our partner Calliditas Therapeutics AB in November 2020. Results from Part A of the NeflgArd study were published in Kidney International in October 2022 which showed urine protein-to-creatinine ratio (UPCR) was 27% lower in the Nefecon group at nine months of treatment compared with placebo, along with a benefit in eGFR preservation corresponding to a 3.87 ml/min/1.73 m2 difference versus placebo. Nefecon was also well-tolerated.
Renal disease is a key focus area for Everest Medicines. In addition to Nefecon, Everest's renal portfolio also includes EVER001, a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development for the treatment of glomerular diseases, and several preclinical programs targeting glomerular nephropathy with the most advanced program expected to enter the clinic in two years.
Nefecon is approved and marketed in the U.S. under the name TARPEYO® and in the E.U. as Kinpeygo®.
Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it reaches the Peyer's patch region of the lower small intestine. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models.
In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas, which gives Everest Medicines exclusive rights to develop and commercialize Nefecon in Mainland China, Hong Kong, Macau, Taiwan and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicine's territories.
About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company's therapeutic areas of interest include cardio-renal diseases, autoimmune disorders, and infectious diseases. For more information, please visit its website at www.everestmedicines.com.
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
i ODD refers to Orphan Drug Designation